Deliberate release into the E.U.
environment of GMOs for any other purposes than placing on the
market:
Trialing of 1507 maize varieties -
Poland - Pioneer Hi-Bred Services GmbH |
Date of publication: February 16,
2005
Source:
http://gmoinfo.jrc.it/gmp_browse_geninf.asp
Notification
report
General information
Notification Number:
B/PL/05/02-01
Member State:Poland
Date of Acknowledgement:27/01/2005
Title of the Project: Trialing of 1507 maize
varieties.
Proposed period of release From:01/04/2005
To:30/11/2007
Name of the Institute(s) or Company(ies): Pioneer
Hi-Bred Services GmbH;
3. Is the same GMPt release planned elsewhere in the
Community?
Not known
4 - Has the same GMPt been notified elsewhere by the same
notifier?
No
Genetically
modified plant
1. Complete name of the
recipient or parental plant(s)
|
Common Name
|
Family Name
|
Genus |
Species
|
Subspecies
|
Cultivar/breeding line
|
| maize
|
poaceae |
zea
|
zea
mays |
mays
|
F1
hybrids of X0842K HX1,LL line |
2. Description of the traits and characteristics which have
been introduced or modified, including marker genes and previous
modifications:
The introduced genes are the cry1F gene from Bacillus
thuringiensis var. aizawai, providing resistance to certain
Lepidopteran insects and the pat gene from Streptomyces
viridochromogenes providing glufosinate-ammonium herbicide
tolerance.
Genetic
modification
3. Type of genetic
modification:
Insertion;
4. In case of insertion of genetic material, give the source
and intended function of each constituent fragment of the region
to be inserted:
ubiZM1(2), Size in bp 1986, ubiquitin promoter (plus 5'
untranslated region) from Zea mays (Christensen et al., 1992,
PMB 18: 675-689).
cry1F, Size in bp 1818 synthetic version of truncated cry1F from
Bacillus thuringiensis var. aizawai (plant-optimized) (Chambers
et al., 1991).
ORF25PolyA, Size in bp 714, Terminator from Agrobacterium
tumefaciens extrachromosomal plasmid pTi15955 (Barker et al.,
1983).
CaMV 35S, Size in bp 554, 35S terminator from Cauliflower Mosaic
Virus
pat 552 synthetic glufosinate-ammonium tolerance gene, based on
a phosphinothricin acetyltransferase gene sequence from
Streptomyces viridochromogenes (Eckes et al., 1989).
CaMV 35S, Size in bp 204, 35S terminator from Cauliflower Mosaic
Virus (Pietrzak M. et al. (1986) Nucleic Acids Res. 14,
5857-5868).
6. Brief description of the method used for the genetic
modification:
The genetic modification has been done by the particle
acceleration method using a "gene gun" to introduce into maize
cells, a linear DNA fragment containing the two genes along with
their regulatory components necessary for expression.
7. If the recipient or parental plant is a forest tree
species, describe ways and extent of dissemination and specific
factors affecting dissemination:
Not applicable.
Experimental
Release
1. Purpose of the release:
The goal of this release is the testing of hybrids in view of
registration on the National List.
2. Geographical location of the site:
Voivodeship: dolnoslaskie, slaskie, wielkopolskie,
wielkopolskie, malopolskie (west, south-west and south part of
Poland)
3. Size of the site (m2):
Size of each 5 testing sites will include ca. 600 m2 and
another ca. 400 m2 of souranding buffer zone. 1507 maize plots
will cover 96 m2 at each of 5 locations.
4. Relevant data regarding previous releases carried out with
the same GM-plant, if any, specifically related to the potential
environmental and human health impacts from the release:
Since 1996 many field trials have already been conducted in
several locations with this genetically modified maize and no
environmental problems were reported for these trials. The
transgenic plants behaved as conventional maize. They were
indistinguishable from the non-genetically modified maize plants
except for being insect resistant and herbicide tolerant, traits
due to the genetic modification.
The placing on the US market of 1507 maize has been authorized
in October 2001 by the American regulatory administrations and
1507 maize has been commercialized in the USA under the trade
name Herculex I Insect Protection.
A dossier for importing 1507 maize in Europe was submitted in
2000 (notification C/NL/00/10). In 2001, a novel food
notification as well as a notification for the cultivation of
1507 maize (notification C/ES/01/01) were submitted.
Environmental
Impact and Risk Management
Summary of the potential
environmental impact from the release of the GMPts:
The e.r.a. has not identified any risks to human and animal
health or the environment from the deliberate release of the
genetically modified maize containing resistance to certain
Lepidopteran insects and tolerance to glufosinate-ammonium. This
is based on the information contained in the notification and
the following concluding remarks:
- There is negligible likelihood for genetically modified maize
to become environmentally persistent or invasive giving rise to
any weediness;
- Expression of the insecticidal crystal protein and the
herbicide tolerance protein does not confer any selective
advantage outside the agricultural environment;
- There are no wild relatives of maize in the EU and the genetic
modification in maize does not introduce any selective
advantages to maize plants outside the heavily managed
agricultural environments;
- The deliberate release of genetically modified maize will
result in negligible immediate and/or delayed environmental
impact resulting from direct and indirect interactions of
genetically modified maize with non-target organisms;
- The genetic modification in maize does not introduce any new
compounds known to cause, or expected to cause, any potential
immediate and/or delayed effects on human health;
- The genetic modification in maize does not introduce any new
compounds known to cause, or expected to cause, any possible
immediate and/or delayed effects on animal health. Moreover, the
genetically modified maize obtained from these field releases
will not enter the feed/food chain.
- The genetic modification will not cause any possible immediate
and/or delayed effects on biogeochemical processes.
- The specific cultivation, management and harvesting techniques
used for the genetically modified maize are identical to those
used for other non-genetically modified maize.
- The potential reduction of the control of certain lepidopteran
insect pests if the target insect pests develop resistance to
the protein as expressed in genetically modified maize has been
identified as the only potential risk resulting from the
interaction of genetically modified maize with target organisms.
Given the size of this deliberate release, the probability of
occurrence of such a phenomenon is negligible. However, an
insect resistance management (IRM) strategy will be developed in
the context of product stewardship when this genetically
modified maize is placed on the European market.
Brief description of any measures taken for the management of
risks:
The shedding of pollen from the genetically modified plants
will be controlled by maintaining a 200-meter isolation distance
with any commercial maize crop. Seed dispersal of individual
kernels does not generally occur. They are fixed on a cob and
enclosed in many husks that protect the seeds from outside
contact. When a few seeds need to be collected for analysis;
this will be done by sampling the whole ear and unused seeds
will be destroyed.
In case of any emergency, the trial could be stopped by
application of a non-selective herbicide other than glufosinate
or by mechanical destruction and incorporation into the soil.
At the end of the release all remaining plant matter that has
not been harvested for analyses will be destroyed by chopping
and incorporating into the soil.
Summary of foreseen field trial studies focused to gain new
data on environmental and human health impact from the release:
Not applicable to this release. |
|
|
|
